| [1]陈峥,王进堂,宋岳涛.老年病诊疗手册[M].北京:中国协和医科大学出版社,2012:243-245.
[2]ZENG C H,CHEN H M,WANG R S,et al.Etiology and clinical characteristics of membranous nephropathy in Chinese patients[J].American Journal of Kidney Diseases,2008,52(3):691-698.
[3]张亚莉,姜莎莎,冯婕,等.不同年龄原发性膜性肾病的临床病理分析[J].中华肾脏病杂志,2012,28(3):241-242.
[4]邹万忠.肾活检病理诊断标准指导意见[J].中华肾脏病杂志,2001,17(8):270-275.
[5]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:156-163.
[6]KATAFUCHI R,KIYOSHI Y,OH Y,et al.Glonerular score as a prognostic factor in IgA nephropathy:its usefulness and limitation[J].Clin Nephrol,1998,49(1):1-8.
[7]MA Y C,ZUO L,CHEN J H,et al.Modied glomerular fitration rate estimating equation for Chinese patients with chronic kidney disease[J].J Am Soc Nephrol,2006,17(10):2937-2944.
[8]李世军.改善全球肾脏病预后组织(KDIGO)临床实践指南:肾小球肾炎[J].肾脏病与透析肾移植,2012,21(3):230-267.
[9]DEEGENS J K,WWTZWLS J F.Membranous nephropsthy in the older adult:epidemiology,diagnosis and management[J].Drugs Aging,2007,24(9):717-732.
[10]方澄清.甲泼尼龙在原发性肾病综合征初发初治患儿的疗效分析[D].杭州:浙江大学,2010.
[11]CHEN W,LIU Q,LIAO Y,et al.Outcomes of tacrolimus therapy in adults with refractory membranous nephrotic syndrome:a prospective,multicenter clinical trial[J].Am J Med Sci,2013,345(2):81-87.
[12]XIE G,XU J,YE C,et al.Immunosuppressive treatment fornephrotic idiopathic membranous nephropathy:a meta-analysis based on Chinese adults[J].PLoS One,2012,7(9):e44330.DOI:10.1371/journal.pone.0044330.
[13]HE L,PENG Y,LIU H,et al.Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids[J].Nephrol,2013,26(3):564-571.
[14]夏梦迪,谢席胜,艾娜.他克莫司治疗膜性肾病进展[J].中国中西医结合肾病杂志,2014,15(10):923-925.
[15]YUAN H,LIN N,SUN G D,et al.Effect of prolonged tacrolimus treatment in idiopathic membranous nephronpathy with nephrotic syndrome[J].Pharmacology,2013,91(5):259-265.
[16]LAN C C,FANG A H,WU P H,et al.Tacrolimus abrogates TGF-β1-inducel type I collage production in normal human fibroblasts through suppressing p38APK signaling pathway:implications on treatment of chronic atopic dermatitis lesions[J].J Eur Acad Dermatol Venereol,2013,10(1):212-215.
[17]SAHIN G,AKAY O M,BAL C,et al.The effect of calcineurin inhibitors on endothelial and platelet function in renal transplant patients[J].Clin Nephrol,2011,76(3):218-225.
[18]高志卿,邓跃毅,王琳,等.陈以平教授分期论治膜性肾病[J].上海中医药杂志,2004,38(2):35-36.
GAO Z Q,DENG Y Y,WANG L,et al.Professor CHEN Yi-ping’s experience in treating membranous nephropathy based on syndrome differentiation in different stages[J].Shanghai Journal of Traditional Chinese Medicine,2004,38(2):35-36.
[19]温长路,刘玉玮,温武兵.医林改错识要[M].北京:中医古籍出版社,2002:157-158.
[20]阮金兰,赵钟祥,曾庆忠,等.赤芍化学成分和药理作用的研究进展[J].中国药理学通报,2003,19(9):965-969.
[21]王晓梅,徐秋萍.痛风宁提取物抑制黄嘌呤氧化酶的研究[J].中医药学报,2013,41(1):57-58.
WANG X M,XU Q P.Inhibitive effect on xathine oxidase by extracts from tongfengning[J].Acta Chinese Medicine and Pharmacology,2013,41(1):57-58.
[22]黎建斌,刘丽萍,丘振文,等.生防风挥发油抗炎止血作用的药理研究[J].新中医,2007,39(7):105-106.
[23]MAK S K,LO K Y,WANG C Y,et al.Treatment with cyclophosphamide in elderly-onset nephrotic syndrome[J].Nephrun Clin Praet,2005,101(1):25-32.
[24]王艺萍,王梅,王素霞,等.老年人原发性膜性肾病肾小动脉病变的特点[J].中华老年医学杂志,2008,27(4):244-247.
WANG Y P,WANG M,WANG S X,et al.The pathological changes of renal arterioIes in the elderIy with idiopathic membranous nephropathy[J].Chinese Journal of Geriatrics,2008,27(4):244-247.
[25]温海燕.黄芪的化学成分研究进展[J].中成药,2006,28(6):879-883.
[26]LEI H,LUO J,TONG L,et al.Quercetin binds to calcineurin at a similar region to cyclosprin A and tacrolimus[J].Food Chem,2011,127(3):1169-1173.
[27]WU L P,LI Q X.Protective effects of quercetin on nephrotoxicity induced by cyclosporine A in rats[J].Chin J Clin Pharmacol Ther,2007,12(6):659-662.
[28]WANG H,ZHOU C L,LEI H,et al.Kaempferol:a new immunosuppressant of calcineurin[J].IUBMB Life,2008,60(8):549-552. |